Kura Oncology, Inc.
KURA
$10.86
$0.777.63%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 36.54% | 29.47% | -67.83% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.54% | 29.47% | -67.83% | -- | -- |
| Cost of Revenue | -1.04% | 17.07% | 23.34% | 62.83% | 58.04% |
| Gross Profit | 13.13% | -12.89% | -3,016.40% | -13.08% | -19.56% |
| SG&A Expenses | 26.15% | 38.19% | 62.60% | 80.64% | 50.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.74% | 23.19% | 35.72% | 68.24% | 55.94% |
| Operating Income | -0.47% | -21.82% | -284.18% | -33.59% | -28.83% |
| Income Before Tax | -3.33% | -28.18% | -370.54% | -36.23% | -30.07% |
| Income Tax Expenses | -- | -96.46% | -96.48% | -- | -- |
| Earnings from Continuing Operations | -3.33% | -27.69% | -321.50% | -36.23% | -30.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.33% | -27.69% | -321.50% | -36.23% | -30.07% |
| EBIT | -0.47% | -21.82% | -284.18% | -33.59% | -28.83% |
| EBITDA | -0.27% | -21.72% | -285.89% | -33.78% | -28.90% |
| EPS Basic | -1.87% | -25.97% | -317.19% | -35.14% | -28.65% |
| Normalized Basic EPS | -1.87% | -26.45% | -191.68% | -35.13% | -28.66% |
| EPS Diluted | -1.87% | -25.97% | -317.19% | -35.14% | -28.65% |
| Normalized Diluted EPS | -1.87% | -26.45% | -191.68% | -35.13% | -28.66% |
| Average Basic Shares Outstanding | 1.45% | 1.37% | 1.05% | 0.80% | 1.10% |
| Average Diluted Shares Outstanding | 1.45% | 1.37% | 1.05% | 0.80% | 1.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |